An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Galafold

Chemical Namemigalastat
Dosage FormCapsules (oral; 123 mg)
Drug ClassMiscellaneous
SystemDigestive, Urinary, Cardiovascular, Skin
CompanyAmicus Therapeutics
Approval Year2018

Indication

  • To treat Fabry disease in adults with an amenable galactosidase alpha gene.
Last updated on 11/2/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Galafold (Migalastat) Prescribing Information 2018Amicus Therapeutics, Cranbury, NJ
Document TitleYearSource
Clinical Review Report: Migalastat (Galafold): (Amicus Therapeutics). 2018CADTH
Migalastat for treating Fabry disease. 2017NICE
Document TitleYearSource
Canadian Fabry disease treatment guidelines 2018. 2019Garrod Association